TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31005386
Drug: Levetiracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (40 mg/kg intravenous or intraosseous infusion over 5 min)
Study: 3115833
Drug: Subcutaneous leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous leuprolide (500 micrograms/day)
Study: 27706483
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 mg, once daily, for 14 days)
Study: 25569053
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture
Study: 25569053
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no subcutaneous suture)
Study: 23678038
Drug: Oral 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17β-estradiol (E₂) at a mean dose of 2 mg
Study: 23678038
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol (E₂) at a mean dose of 0.1 mg
Study: 20519423
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mL (50 microg) added to local anesthetics
Study: 20519423
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo 1 mL
Study: 14669194
Drug: High-frequency vibration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency vibration training (28Hz) for three 2-minute sessions, twice weekly for 6 months
Study: 10974208
Drug: CDP‐choline (citicoline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP‐choline (citicoline; 500 mg)
Study: 10974208
Drug: CDP‐choline (citicoline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP‐choline (citicoline; 2000 mg)
Study: 10974208
Drug: CDP‐choline (citicoline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP‐choline (citicoline; 4000 mg)
Study: 8396833
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 12 mg
Study: 3520601
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg clotrimazole vaginal tablets once daily for 3 consecutive days
Study: 3520601
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg terconazole vaginal tablets once daily for 3 consecutive days
Study: 3520601
Drug: one 240
Normalized name: dipyrone 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 240 mg terconazole vaginal tablet followed by 2 identical placebo pessaries
Study: 28387895
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/die)
Study: 23704994
Drug: Eplerenone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25-50 mg)
Study: 22470245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 8 mg Ondansetron
Study: 22470245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Ondansetron
Study: 11435263
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 37.5 mg/day
Study: 17660491
Drug: Single-agent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine
Study: 2866134
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg twice daily
Study: 102674
Drug: Chewable fluoride
Normalized name: sodium fluoride Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable fluoride tablets (1 mg of fluoride) once a day
Study: 102674
Drug: Chewable fluoride
Normalized name: sodium fluoride Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable fluoride tablets (1 mg of fluoride) twice a day
Study: 102674
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once a day
Study: 16895262
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (6 g nightly for 4 weeks, then increased to 9 g nightly for 4 additional weeks)
Study: 9822507
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (8 mg every 12 hours for a total of 4 doses)
Study: 8126916
Drug: Intravenous epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epirubicin (Group C)
Study: 8126916
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant therapy (Group A)
Study: 2536462
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, methotrexate 40 mg/m2, cisplatin 40 mg/m2 every 28 days)
Study: 2536462
Drug: Sequential single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single-agent chemotherapy (mitomycin C 10 mg/m2 monthly until progression, vinblastine 5 mg/m2 every 2 weeks until progression, methotrexate 40 mg/m2 weekly until relapse)
Study: 4913786
Drug: Oral prethcamide
Normalized name: prethcamide
DrugBank: Prethcamide (DB13447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prethcamide (200 mg, four times daily)
Study: 4913786
Drug: Oral prethcamide
Normalized name: prethcamide
DrugBank: Prethcamide (DB13447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prethcamide
Study: 25980660
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (50 L/min, FiO2 50%)
Study: 18518888
Drug: Subcutaneous sweat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sweat gland suction curettage (SSGSC)
Study: 12492725
Drug: Desloratadine, 5
Normalized name: Desloratadine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine, 5 mg once daily
Study: 12560306
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% (L)
Study: 12560306
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% plus sufentanil 0.75 microg (L+S)
Study: 2543596
Drug: sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium cromoglycate (SCG) (7.3 +/- 0.6 mg)
Study: 2543596
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (NED) (7.5 +/- 0.6 mg)
Study: 12474070
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of red wine (12 % ethanol)
Study: 7606610
Drug: Neomycin sulfate,
Normalized name: Neomycin Sulfate, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin sulfate, bacitracin zinc, and polymyxin B sulfate combination (NEO)
Study: 2141773
Drug: Sufentanil in
Normalized name: sufentanil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil in one of four doses: 30 micrograms/kg as a single dose, 10 micrograms/kg plus infusion 0.05 microgram.kg‐1.min‐1, 20 micrograms/kg plus infusion 0.1 microgram.kg‐1.min‐1, or 40 micrograms/kg plus infusion 0.2 microgram.kg‐1.min‐1
Study: 27798731
Drug: Aggressive strategy
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive strategy targeting LDL-C of 70 mg/dL and BP of 120/70 mmHg
Study: 26277774
Drug: Sertraline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75 mg)
Study: 3517388
Drug: Crystalloid cardioplegia
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid cardioplegia (CC)
Study: 1863945
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of famotidine nightly for four to eight weeks
Study: 1863945
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ranitidine nightly for four to eight weeks
Study: 1863945
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ranitidine nightly during six-month maintenance treatment
Study: 6849826
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 mg twice weekly for 1 year)
Study: 6849826
Drug: Phlebotomy (twice-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (twice-monthly phlebotomies of 400 ml whole blood for 1 year)
Study: 9281302
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole daily
Study: 20198424
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole and 300 mg rebamipide daily
Study: 15746835
Drug: Almond intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond intake (dose-response effect)
Study: 14518160
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (up to 400 mg/day)
Study: 10380063
Drug: 13-day titration
Normalized name: memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-day titration group to 150 mg/day
Study: 10380063
Drug: 16-day titration
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 16-day titration group to 200 mg/day
Study: 10380063
Drug: 10-day titration
Normalized name: memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day titration group
Study: 9408278
Drug: Surgery (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (primary treatment for cutaneous malignant melanoma)
Study: 8228191
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (enalapril or lisinopril 20 mg once a day)
Study: 8228191
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nifedipine 20 mg twice a day or lacidipine 4 mg once a day)
Study: 2937811
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg/d
Study: 2937811
Drug: Aspirin 3,900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3,900 mg/d
Study: 2937811
Drug: Etodolac 100
Normalized name: etodolac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 100 mg/d
Study: 2937811
Drug: Etodolac 50
Normalized name: etodolac 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 50 mg/d
Study: 27503012
Drug: Telmisartan combined
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan combined with leflunomide (20 mg/d)
Study: 17460947
Drug: BB536 yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB536 yogurt (2 x 100 g per day for 14 weeks)
Study: 17460947
Drug: Placebo yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yogurt (2 x 100 g per day for 14 weeks)
Study: 7966027
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml 0.9% normal saline)
Study: 3331977
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg orally) in short children (SC) vs Insulin hypoglycaemia (IH)
Study: 21712486
Drug: LCS101 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCS101 (2 g capsules thrice daily)
Study: 15609595
Drug: Guben Xiaoliu
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guben Xiaoliu Capsule (GXC) plus chemotherapy (CT) in Group A
Study: 15609595
Drug: Guben Xiaoliu
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guben Xiaoliu Capsule (GXC) alone in Group B
Study: 15609595
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) alone in Group C
Study: 17587389
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg)
Study: 2884197
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms/hr i.v. for 7 days after initial treatment)
Study: 2884197
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after initial treatment)
Study: 31136042
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (5000 IU daily for 80 days)
Study: 31136042
Drug: Stoss therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoss therapy (100,000 IU weekly for 4 weeks)
Study: 19263185
Drug: Early regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early regular daily feeding with cow's milk-based formula
Study: 11581005
Drug: Micronized DHEA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized DHEA, 25 mg/day for 12 months
Study: 8267129
Drug: Clozapine (410.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (410.5 mg/day, SD = 45.8)
Study: 8267129
Drug: Haloperidol (24.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (24.8 mg/day, SD = 5.5)
Study: 31385847
Drug: Information given
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information given about initiation of opioid use (received prescription opioids from a doctor)
Study: 31385847
Drug: Information given
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information given about initiation of opioid use (took prescription opioids from a friend)
Study: 27028445
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus low-dose aspirin (75 mg)
Study: 12814449
Drug: Netilmicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (100 mg) administered as a maximum of four successive intravenous infusions of 30 min, at 8-h intervals.
Study: 1644095
Drug: Aggressive lipid-altering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-altering therapy
Study: 23270333
Drug: LI10903F (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI10903F (300 mg thrice daily)
Study: 23270333
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg thrice daily)
Study: 19900236
Drug: Pioglitazone (force-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (force-titrated to 45 mg/day, n = 654)
Study: 15758560
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (100 g) administered at -30 min followed by TRH (200 microg iv) at 0 min
Study: 15758560
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (100 g) at -30 min and isoproterenol infused continuously with TRH (200 microg iv) at 0 min
Study: 9794346
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg carvedilol twice daily
Study: 9794346
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol twice daily
Study: 1978474
Drug: Remoxipride (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (150-600 mg daily for 6 weeks)
Study: 1978474
Drug: Haloperidol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-20 mg daily for 6 weeks)
Study: 15155391
Drug: Diet eliminating
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet eliminating artificial colourings and benzoate preservatives for one week followed by a three week double blind crossover study with a drink containing artificial colourings (20 mg daily) and sodium benzoate (45 mg daily) during active periods.
Study: 11549686
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.3 mg/kg/week
Study: 9039927
Drug: CsA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA plus steroids (group 2)
Study: 9039927
Drug: CsA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA plus steroids plus azathioprine (group 3)
Study: 7895587
Drug: rhGM‐CSF (leucomax)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF (leucomax) with chemotherapy
Study: 7895587
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only chemotherapy)
Study: 3285117
Drug: 60 or
Normalized name: QM-260 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 or 85 g fructose
Study: 29086614
Drug: Cannabidiol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (600 mg)
Study: 29884082
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol premedication
Study: 26965503
Drug: 80-kV protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-kV protocol A (PA; 0.75 g iodine/kg)
Study: 26965503
Drug: 120-kV standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-kV standard protocol (PS; 0.75 g iodine/kg)
Study: 23981616
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus of urokinase (250 kU/20 ml)
Study: 12017348
Drug: Fiduxosin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin 30 mg
Study: 12017348
Drug: Fiduxosin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin 60 mg
Study: 12017348
Drug: Fiduxosin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin 90 mg
Study: 12005359
Drug: Fiduxosin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin 120 mg
Study: 7751411
Drug: Intravenous flucloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flucloxacillin (500 mg)
Study: 7751411
Drug: Oral flucloxacillin
Normalized name: cloxacillin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flucloxacillin (500 mg)
Study: 2268141
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 U/kg)
Study: 10737700
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration
Study: 29252175
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin solution
Study: 25675380
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg bid) for 6 months
Study: 23307540
Drug: Recommendations related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations related to medication errors
Study: 23307540
Drug: Recommendations related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations related to drug indications
Study: 23307540
Drug: Recommendations related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations related to drug efficacy
Study: 23307540
Drug: Recommendations related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations related to therapeutic drug and disease state monitoring
Study: 23307540
Drug: Recommendations for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for patients with a greater number of drugs
Study: 19451321
Drug: 1% tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tenofovir gel
Study: 20003839
Drug: Metformin (2x500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2x500 mg/day)
Study: 10921701
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (loading dose of 150 mg and maintenance dose of 0.4 mg x kg(‐1) x h(‐1) for 3 days before and 5 days after operation)
Study: 10921701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (matching infusions of 5% glucose solution)
Study: 11953190
Drug: Tetramethylpyrazine (TMPZ)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMPZ) 4 mg/kg injected intravenously before blood collection and added to washing fluid.
Study: 11953190
Drug: Tetramethylpyrazine (TMPZ)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMPZ) 4 mg/kg injected intravenously before blood collection, but not added to washing fluid.
Study: 10190648
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg L-tartrate orally twice daily for 6 days
Study: 7585998
Drug: Mid-laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-laser therapy
Study: 27161966
Drug: Hydrocortisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (10 mg/m²/d)
Study: 22330085
Drug: IFN‐γ treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐γ treatment
Study: 22330085
Drug: TMP‐SMX treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMX treatment
Study: 17942817
Drug: Albuterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (12 mg per day)
Study: 8281355
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunotherapy)
Study: 19258143
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 1% lidocaine
Study: 12598278
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 3% lidocaine
Study: 25111080
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose ATG (lowATG) 2.25 mg/kg
Study: 8129455
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - transdermal oestradiol (50 micrograms daily)
Study: 2569851
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL syrup of ipecac
Study: 3345017
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g activated charcoal-sorbitol solution
Study: 11292231
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin
Study: 26645467
Drug: Diet Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet Therapy
Study: 26645467
Drug: Diet-Plus-Statin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-Plus-Statin Therapy and Diet Therapy
Study: 23070986
Drug: Propranolol (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.035 mg/kg body weight i.v.)
Study: 18779885
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment twice daily with occlusive dressings